AI Terminal
Ion Beam Applications, SA
Transaction in Own Shares • Apr 1, 2021
3960_dirs_2021-04-01_dba64429-3077-4703-a309-835622a4cff3.pdf
Transaction in Own Shares
Open in ViewerOpens in native device viewer
IBA – ACQUISITION OF OWN SHARES
Immediate Release – April 1 st, 2021
Louvain-la-Neuve, Belgium, April 1 st , 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA ("IBA") hereby discloses information in relation to its share buyback program announced on January 12th, 2021.
Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company's obligations under a long term incentive plan for certain members of its personnel.
In the framework of this share buyback program, IBA repurchased 15.288 IBA shares on Euronext Brussels in the period from March 26th , 2021 up to and including April 1 st , 2021, as follows:
| Trade date | Shares | Average | Min price | Max price | Buyback |
|---|---|---|---|---|---|
| purchased | price | amount | |||
| 26-03-21 | 2.200 | 15,00 € | 14,80 € | 15,10 € | 33.000,88 € |
| 29-03-21 | 4.200 | 15,65 € | 15,50 € | 15,80 € | 65.745.96 € |
| 30-03-21 | 3.431 | 15,98 € | 15,66 € | 16,00 € | 54.831,84 € |
| 31-03-21 | 2.757 | 16,28 € | 16,08 € | 16,40 € | 44.892.23 € |
| 01-04-21 | 2.700 | 16,44 € | 16,30 € | 16,48 € | 44.381,79 € |
| TOTAL | 15.288 | 15,89 € | 14,80 € | 16,48 € 242.852,70 € |
The total number of shares purchased under this program therefore amounts to 233.613. As a result, IBA SA currently holds 707.834 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,35% of its share capital.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com
Press release | 01/04/2021
Press release
Inside / regulated information
Contact person IBA Christian Matton, Chief Legal Officer [email protected]
Press release | 01/04/2021
IBA | Ion Beam Applications Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Nivelles | VAT BE0428.750.985 T +32 10 47 58 11 | F +32 10 47 58 10 | [email protected] | iba-worldwide.com
